


Herpesviridae

VIRION



Enveloped, spherical to pleomorphic, 150-200 nm in diameter, **T=16 icosahedral symmetry**. Capsid consists of 162 capsomers and is surrounded by an amorphous tegument. Glycoproteins complexes are embed in the lipid envelope.

GENOME

Monopartite, linear, dsDNA genome of 120-240 kb. The genome contains terminal and internal reiterated sequences.

GENE EXPRESSION

Each viral transcript usually encodes a single protein and has a promoter/regulatory sequence, a TATA box, a transcription initiation site, a 5' leader sequence of 30-300 bp (not translated), a 3' non-translated sequence of 10-30 bp, and a poly A signal. There are many gene overlaps. There are only few spliced genes. Some of the expressed ORFs are antisense to each other. Some ORFs can be accessed from more than one promoter. Certain proteins are downregulated translationally by a **leaky scanning** from an upstream ORF.

REPLICATION

NUCLEAR

Lytic replication:

1. **Attachment** of the viral gB, gC, gD and gH proteins to host receptors mediates endocytosis of the virus into the host cell.
2. **Fusion with the plasma membrane** to release the core and the tegument proteins into the host cytoplasm.
3. The capsid is **transported to the nuclear pore** where **viral DNA is released into the nucleus**.
4. Transcription of immediate early genes which promote transcription of early genes and protect the virus against innate host immunity.
5. Transcription of early viral mRNA by host polymerase II, encoding proteins involved in replication of the viral DNA.
6. A first round of circular genome amplification occurs by **bidirectional replication**
7. Synthesis of linear concatemer copies of viral DNA by **rolling circle**.
8. Transcription of late mRNAs by host polymerase II, encoding structural proteins.
9. **Assembly** of the virus in **nuclear viral factories** and **budding through the inner lamella of the nuclear membrane** which has been modified by the insertion of herpes glycoproteins, throughout the Golgi and **final release at the plasma membrane**.

Latent replication : replication of circular viral episome in tandem with the host cell DNA using the host cell replication machinery.

DB LINKS

Nucleotide DB: [NCBI](#)

Protein DB: [UniProtKB](#)

Virus DB: [VBRC genome browser](#)



TAXONOMY

Group I: dsDNA viruses

Order: **Herpesvirales**

Family: **Herpesviridae**

Subfamily: **Alphaherpesvirinae**

Genus: **Iltovirus**

Mardivirus

Scutavirus

Simplexvirus

Varicellovirus

Subfamily: **Betaherpesvirinae**

Genus: **Cytomegalovirus**

Muromegalovirus

Roseolovirus

Proboscivirus

Subfamily: **Gammaherpesvirinae**

Genus: **Lymphocryptovirus**

Rhadinovirus

Macavirus

Percavirus

SPECIES



Host

NATURAL HOSTS

Vertebrates

CELL TROPISM

INTERACTIONS

Cell receptors **HHV-1** and **HHV-2**:
heparan sulfate, **TNFRSF14** **PVRL1**

HHV-2: **PVRL2**

BoHV: heparan sulfate, **CD155** **PVRL1**

SuHV-1: heparan sulfate, **CD155**

PVRL1 **PVRL2**

HHV-7: **CD4**

HHV-8: **Integrin alphaV-beta3**

HHV-4: **CR2** **BMRF2**

HHV-5: heparan sulfate

[Host-virus interaction](#)

Ecology and disease

GEOGRAPHY

Worldwide

ASSOCIATED DISEASES

HHV-1 and **HHV-2**: skin vesicles or mucosal ulcers (oral and/or genital). Rarely, encephalitis and meningitis.

HHV-3: chickenpox (Varicella) and shingles. Congenital varicella syndrome may be caused by infection in utero during the first trimester.

GaHV-2: Marek's disease.

HHV-5: congenital CMV infection.

HHV-6: "sixth disease" (roseola infantum, exanthem subitum).

HHV-7: symptoms analog to the "sixth disease".

HHV-4: B lymphocytes.

HHV-8: B lymphocytes.

TRANSMISSION

HHV-1: contact with lesions and body fluids.

HHV-2: sexual. Infection at birth by a genitally-infected mother.

HHV-3: contact, respiratory route.

HHV-5: Infected body fluids (urine, saliva), transplacental, transplantation, blood transfusion.

HHV-4: Saliva, sexual (probable), transplacental.

HHV-8: Saliva, sexual.

VACCINE**ANTIVIRAL DRUGS**

Nucleoside analogs (Acyclovir, famcyclovir, valacyclovir...). These drugs are activated by the viral specific enzyme, thymidine kinase, and are therefore specific to herpes-infected cells. These drugs act against the replicating virus (they are incorporated into the DNA as it is copied) and are ineffective against a latent virus.